

## Supporting Information

### Targeting xanthine oxidase degradation via PROTAC technology for the treatment of hyperuricaemia

Xue Dong,<sup>a,b</sup> Lin Wang,<sup>a,b</sup> Sijia Lin,<sup>a,b</sup> Ziyi Wang,<sup>a,b</sup> Xueyong Qi,<sup>a</sup> Jin Cao,<sup>a</sup> Jing Zhang,<sup>a</sup> Lin Wu,<sup>\*b</sup> Song Shen<sup>\*a</sup>

<sup>a</sup> College of Pharmaceutical Sciences, Jiangsu University, Zhenjiang, Jiangsu 212013, China

<sup>b</sup> Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China

\* Corresponding authors.

E-mail addresses: [jsdx.shensong@163.com](mailto:jsdx.shensong@163.com) (S. Shen), [linmeimei1983@163.com](mailto:linmeimei1983@163.com) (L. Wu).




Figure S1. <sup>1</sup>H NMR of intermediate 1.




Figure S2.  $^{13}\text{C}$  NMR of intermediate 1.





Figure S3. MS spectrum of intermediate 1.



| Retention time (min) | Area (%) |
|----------------------|----------|
| 8.108                | 96.57    |

Figure S4. HPLC of intermediate 1.




Figure S5.  $^1\text{H NMR}$  of intermediate 2.




Figure S6.  $^{13}\text{C}$  NMR of intermediate 2.





Figure S7. MS spectrum of intermediate 2.



| Retention time (min) | Area (%) |
|----------------------|----------|
| 6.270                | 98.78    |

Figure S8. HPLC of intermediate 2.




Figure S9. <sup>1</sup>H NMR DeXOD.




Figure S10. <sup>13</sup>C NMR DeXOD.





Figure S11. MS spectrum of DeXOD.



| Retention time (min) | Area (%) |
|----------------------|----------|
| 8.905                | 99.44    |

Figure S12. HPLC of DeXOD.




Figure S13. Fluorescence diagram of DeXOD, Intermediate, Thalidomide fluoride, febuxostat




Figure S14. Hemolysis detection at different DeXOD concentrations.




Figure S15. Laser confocal images showing the uptake of different concentrations of DeXOD by HePG2 cells.




Figure S16. Western blotting image after pretreating the cells with febuxostat and then adding DeXOD and only DeXOD alone.




Figure S17. Western blotting image of XOD protein recovery following DeXOD washout.




Figure S18. Western blotting image of re-degradation of XOD by DeXOD in a re-challenge assay in cells.